---
title: "Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development"
id: "nature-0-the-next-generation-of-antibody-drug-conjugates"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04543-y"
published_at: "2026-08-03T10:59:57.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Next-generation Antibody–Drug Conjugates: Strategies to Improve Efficacy and Clinical Development
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-the-next-generation-of-antibody-drug-conjugates
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04543-y)
- **Published At:** 2026-08-03T10:59:57.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Antibody–drug conjugates (**ADCs**) couple a monoclonal antibody to a cytotoxic payload to deliver high concentrations of drug to cancer cells. - Advances in understanding ADC mechanisms of action and resistance have driven innovations in ADC chemistry and informed rational therapeutic combinations. - The current rate of innovation in ADC design outpaces clinical trial capacity, making it difficult to test each incremental change in isolation. - Single modifications or single-agent combinations are unlikely to produce major clinical gains; integrating multiple chemistry advances into single ADC constructs is needed. - There is a call for frameworks, infrastructures and tools to accelerate and de-risk preclinical and early clinical ADC development. - Development of multidimensional molecular predictors of ADC sensitivity could enable better patient selection and personalized treatment strategies. - Using new ADCs earlier in disease (for example, in early-stage cancers) may increase clinical benefit. - A long-term vision is to generate diversified ADC libraries with varied constructs and drug-to-antibody ratios to match individual tumor biology. - Figures in the source outline integrated strategies to maximize ADC potential, mechanisms of ADC action and resistance, strategies to enhance efficacy and combinations, and a strategic framework to expand clinical impact. - References cited include recent pivotal clinical and translational studies that illustrate clinical successes, mechanistic insights and safety considerations for ADCs, including examples of lung toxicity and tumor-penetration challenges.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04543-y#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04543-y) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ About the Editors ](https://www.nature.com/nm/editors) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [perspectives](https://www.nature.com/nm/articles?type=perspective) 4. article * Perspective * Published: 03 August 2026 # The next generation of antibody–drug conjugates * [F. Mosele](https://www.nature.com/articles/s41591-026-04543-y#auth-F_-Mosele-Aff1-Aff2-Aff3) [ORCID: orcid.org/0000-0001-7841-2900](https://orcid.org/0000-0001-7841-2900)[1](https://www.nature.com/articles/s41591-026-04543-y#Aff1),[2](https://www.nature.com/articles/s41591-026-04543-y#Aff2),[3](https://www.nature.com/articles/s41591-026-04543-y#Aff3), * [A. Peltier](https://www.nature.com/articles/s41591-026-04543-y#auth-A_-Peltier-Aff2)[2](https://www.nature.com/articles/s41591-026-04543-y#Aff2) [na1](https://www.nature.com/articles/s41591-026-04543-y#na1), * [Y. Ozaki](https://www.nature.com/articles/s41591-026-04543-y#auth-Y_-Ozaki-Aff4)[4](https://www.nature.com/articles/s41591-026-04543-y#Aff4) [na1](https://www.nature.com/articles/s41591-026-04543-y#na1), * [A. Detappe](https://www.nature.com/articles/s41591-026-04543-y#auth-A_-Detappe-Aff5-Aff6-Aff7-Aff8)[5](https://www.nature.com/articles/s41591-026-04543-y#Aff5),[6](https://www.nature.com/articles/s41591-026-04543-y#Aff6),[7](https://www.nature.com/articles/s41591-026-04543-y#Aff7),[8](https://www.nature.com/articles/s41591-026-04543-y#Aff8), * [J. C. Soria](https://www.nature.com/articles/s41591-026-04543-y#auth-J__C_-Soria-Aff9-Aff10)[9](https://www.nature.com/articles/s41591-026-04543-y#Aff9),[10](https://www.nature.com/articles/s41591-026-04543-y#Aff10) & * … * [F. André](https://www.nature.com/articles/s41591-026-04543-y#auth-F_-Andr_-Aff2-Aff3-Aff9-Aff11)[2](https://www.nature.com/articles/s41591-026-04543-y#Aff2),[3](https://www.nature.com/articles/s41591-026-04543-y#Aff3),[9](https://www.nature.com/articles/s41591-026-04543-y#Aff9),[11](https://www.nature.com/articles/s41591-026-04543-y#Aff11) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04543-y#citeas) [ Save article ](https://www.nature.com/articles/s41591-026-04543-y/save-research?_csrf=MbirSfkJY2XbwABVO7EQgFYQT4brAp-a) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Antibody–drug conjugates (ADCs)—composed of a monoclonal antibody linked to a payload—were designed to deliver high concentrations of cytotoxic agents to cancer cells. Since their inception, a deeper understanding of the mechanisms of action and resistance to ADCs in patients has generated a wealth of advances in the chemistry of ADC constructs, together with rational therapeutic combinations. However, the pace of innovation now exceeds clinical trial capacity. Also, any single modification or combination is unlikely to generate clinically meaningful benefit on its own. In this context, there is a need to integrate multiple chemistry advances into individual ADCs and to develop frameworks, infrastructures and tools to accelerate and de-risk the preclinical and early clinical development of these agents. In addition, the development of multidimensional molecular tools to predict ADC sensitivity, together with the optimal use of new ADCs in early-stage cancers, should contribute to improved outcomes for patients. We discuss these opportunities and challenges and predict that in the longer term, the development of diversified ADC libraries incorporating distinct constructs and drug-to-antibody ratios will enable personalized treatment strategies aligned with individual tumor biology. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04543-y) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04543-y) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue [Learn more](https://www.nature.com/nm/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04543-y) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Integrated strategy to maximize the potential of next-generation ADCs in patients.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04543-y/MediaObjects/41591_2026_4543_Fig1_HTML.png) **Fig. 2: Understanding mechanisms of ADC action, adaptation and resistance in patients to refine ADC development.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04543-y/MediaObjects/41591_2026_4543_Fig2_HTML.png) **Fig. 3: Strategies to enhance ADC efficacy and therapeutic combinations in patients.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04543-y/MediaObjects/41591_2026_4543_Fig3_HTML.png) **Fig. 4: Strategic framework to accelerate clinical research and expand the clinical impact of ADCs.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04543-y/MediaObjects/41591_2026_4543_Fig4_HTML.png) ## References 1. André, F. et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. _Lancet_ **401** , 1773–1785 (2023). [Article](https://doi.org/10.1016%2FS0140-6736%2823%2900725-0) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37086745) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trastuzumab%20deruxtecan%20versus%20treatment%20of%20physician%E2%80%99s%20choice%20in%20patients%20with%20HER2-positive%20metastatic%20breast%20cancer%20%28DESTINY-Breast02%29%3A%20a%20randomised%2C%20open-label%2C%20multicentre%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2823%2900725-0&volume=401&pages=1773-1785&publication_year=2023&author=Andr%C3%A9%2CF) 2. Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. _N. Engl. J. Med._ **387** , 9–20 (2022). [Article](https://doi.org/10.1056%2FNEJMoa2203690) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35665782) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561652) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xit1ersLbF) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Trastuzumab%20deruxtecan%20in%20previously%20treated%20HER2-low%20advanced%20breast%20cancer&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2203690&volume=387&pages=9-20&publication_year=2022&author=Modi%2CS) 3. Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. _Cancer Cell_ **40** , 1255–1263 (2022). [Article](https://doi.org/10.1016%2Fj.ccell.2022.09.016) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36240779) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38Xis1eiu7jI) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20therapeutic%20window%20of%20antibody%20drug%20conjugates%3A%20a%20dogma%20in%20need%20of%20revision&journal=Cancer%20Cell&doi=10.1016%2Fj.ccell.2022.09.016&volume=40&pages=1255-1263&publication_year=2022&author=Colombo%2CR&author=Rich%2CJR) 4. Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. _Cancer Discov._ **14** , 2089–2108 (2024). [Article](https://doi.org/10.1158%2F2159-8290.CD-24-0708) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39439290) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXlslKitrk%3D) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20journey%20of%20antibody-drug%20conjugates%3A%20lessons%20learned%20from%2040%20years%20of%20development&journal=Cancer%20Discov.&doi=10.1158%2F2159-8290.CD-24-0708&volume=14&pages=2089-2108&publication_year=2024&author=Colombo%2CR&author=Tarantino%2CP&author=Rich%2CJR&author=LoRusso%2CPM&author=Vries%2CEGE) 5. Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P. & Thurber, G. M. Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment. _Nat. Rev. Cancer_ (2025). [Article](https://doi.org/10.1038%2Fs41568-025-00869-w) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41039110) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Unveiling%20the%20molecular%20and%20immunological%20drivers%20of%20antibody-drug%20conjugates%20in%20cancer%20treatment&journal=Nat.%20Rev.%20Cancer&doi=10.1038%2Fs41568-025-00869-w&publication_year=2025&author=Zippelius%2CA&author=Tolaney%2CSM&author=Tarantino%2CP&author=Balthasar%2CJP&author=Thurber%2CGM) 6. Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. _Nat. Rev. Clin. Oncol._ **18** , 327–344 (2021). [Article](https://doi.org/10.1038%2Fs41571-021-00470-8) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33558752) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287784) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Unlocking%20the%20potential%20of%20antibody-drug%20conjugates%20for%20cancer%20therapy&journal=Nat.%20Rev.%20Clin.%20Oncol.&doi=10.1038%2Fs41571-021-00470-8&volume=18&pages=327-344&publication_year=2021&author=Drago%2CJZ&author=Modi%2CS&author=Chandarlapaty%2CS) 7. Zhang, Z. et al. Results from a phase 1/2 study of 7MW3711: a novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors. _J. Clin. Oncol._ **43** , 3035 (2025). [Article](https://doi.org/10.1200%2FJCO.2025.43.16_suppl.3035) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Results%20from%20a%20phase%201%2F2%20study%20of%207MW3711%3A%20a%20novel%20B7-H3%20antibody-drug%20conjugate%20%28ADC%29%20incorporating%20a%20topoisomerase%20I%20inhibitor%20in%20patients%20with%20advanced%20solid%20tumors&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2025.43.16_suppl.3035&volume=43&publication_year=2025&author=Zhang%2CZ) 8. Bardia, A. et al. Final results from the randomized phase III ASCENT clinical irial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. _J. Clin. Oncol._ **42** , 1738–1744 (2024). [Article](https://doi.org/10.1200%2FJCO.23.01409) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38422473) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107894) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXhtVGks73L) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Final%20results%20from%20the%20randomized%20phase%20III%20ASCENT%20clinical%20irial%20in%20metastatic%20triple-negative%20breast%20cancer%20and%20association%20of%20outcomes%20by%20human%20epidermal%20growth%20factor%20receptor%202%20and%20trophoblast%20cell%20surface%20antigen%202%20expression&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.23.01409&volume=42&pages=1738-1744&publication_year=2024&author=Bardia%2CA) 9. Wei, Q. et al. Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan. _Cancer Res._ **85** , 2081–2099 (2025). [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40300097) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Perivascular%20niche-resident%20alveolar%20macrophages%20confer%20interstitial%20pneumonitis%20related%20to%20trastuzumab%20deruxtecan&journal=Cancer%20Res.&volume=85&publication_year=2025&author=Wei%2CQ) 10. Koganemaru, S. et al. Potential mechanisms of interstitial lung disease induced by antibody–drug conjugates based on quantitative analysis of drug distribution. _Mol. Cancer Ther._ **24** , 242–250 (2025). [Article](https://doi.org/10.1158%2F1535-7163.MCT-24-0267) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39450538) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791479) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXosFSjsr8%3D) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Potential%20mechanisms%20of%20interstitial%20lung%20disease%20induced%20by%20antibody%E2%80%93drug%20conjugates%20based%20on%20quantitative%20analysis%20of%20drug%20distribution&journal=Mol.%20Cancer%20Ther.&doi=10.1158%2F1535-7163.MCT-24-0267&volume=24&pages=242-250&publication_year=2025&author=Koganemaru%2CS) 11. Cilliers, C., Menezes, B., Nessler, I., Linderman, J. & Thurber, G. M. Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival. _Cancer Res._ **78** , 758–768 (2018). [Article](https://doi.org/10.1158%2F0008-5472.CAN-17-1638) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29217763) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVWntr8%3D) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Improved%20tumor%20penetration%20and%20single-cell%20targeting%20of%20antibody-drug%20conjugates%20increases%20anticancer%20efficacy%20and%20host%20survival&journal=Cancer%20Res.&doi=10.1158%2F0008-5472.CAN-17-1638&volume=78&pages=758-768&publication_year=2018&author=Cilliers%2CC&author=Menezes%2CB&author=Nessler%2CI&author=Linderman%2CJ&author=Thurber%2CGM) 12. Rubahamya, B., Dong, S. & Thurber, G. M. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. _Sci. Adv._ **10** , eadk1894 (2024). [Article](https://doi.org/10.1126%2Fsciadv.adk1894) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38820153) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141632) [CAS](https://
## Related Clinical Research

- [VISTA: Virtual spatial transcriptomics from H&E for prognostic and therapy response prediction in](https://medichelpline.com/clinical-feed/biorxiv-21-virtual-spatial-transcriptomics-from-histopathology-enables-prognostic-and.md)
- [Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive](https://medichelpline.com/clinical-feed/journal-of-clinical-oncology-23-neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-the-randomized-noninferiority-phase-iii-neocarhp-trial.md)
- [Chemotherapy-Associated Colitis After TCbHP in HER2-Positive Breast Cancer: Case Report](https://medichelpline.com/clinical-feed/pubmed-42571049.md) (DOI: 10.12659/AJCR.952507)
- [Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer](https://medichelpline.com/clinical-feed/nejm-11-trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer.md)
- [Sympathetic Overdrive, Vascular Dysfunction, and Exercise Intolerance in Long-Term Breast Cancer](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-65-sympathetic-neural-overactivation-vascular-dysfunction-and-exercise-intolerance-in-long-term-survivors-of-breast-cancer-treated-with-doxorubicin-and-trastuzumab-based-chemotherapy.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.